الفهرس 
INTRODUCTIONOnly 14 pages are availabe for public view
 |  | from | 94 |  |  |
| | | from | 94 | | |
Abstract
DM patients are a high-risk subgroup for PCI and represent a significant percentage of the PCI population. Drug-eluting stents (DES) improve vessel patency over BMS in DM patients by greatly reducing neointimal proliferation. However, DM remains associated with higher rates of restenosis in the DES era. Myeloperoxidase (MPO) is a haeme enzyme that is abundant in granules of human inflammatory cells. MPO acts as a master enzyme in the generation of a range of reactive oxygen species.
Aim of the Work
The aim of this study is to describe the procedural and clinical outcomes of diabetic patients undergoing PCI using drug eluting stents in comparison with non-diabetic patients as regards the major adverse cardiac events, stroke and major bleeding during the hospital stay, and at the end of follow up period, and the relation of these outcomes to oxidative stress.
Methods
100 diabetic patients and 100 non-diabetic patients with chronic stable angina undergoing percutaneous coronary intervention with drug eluting stents had their serum myeloperoxidase and their red cell distribution width assessed and followed up for six months for major adverse cardiac events.